We found significantly less treatment discontinuation and lower risk of hypoglycemia in patients with type 2 diabetes newly dispensed with DPP-4 inhibitors compared to those initiating NPH insulin, when these agents were used as third-line therapy after metformin and sulfonylurea. The gene discussed is INS; the disease is type 2 diabetes mellitus.